X

StockGuru Blog: Medify Solutions – Licensing Model with Three Month Cash Flow Examined

Medify Solutions Limited – MFYS

Over the past month, Medify Solutions Limited has conducted a full and extensive review of its commercial model being operated and going forward in the UK, European and global markets. This exercise has examined the various options that exist in the market, with the prime focus of adopting the one which shows the greatest potential for rapid revenue growth and enhancement of the shareholder value in Medify Solutions.

The fundamental approaches that result from this exercise, include one of Medify Solutions always (directly or indirectly) owning the installed customer that is utilizing a Medify solution.

Based on a licensing agreement sales model at a minimum order quantity of 5 and reoccurring revenues with a minimum contractual period of 24 months. The headline financial results show a projected income model with a gross profit margin of around 78%, with a licensing model showing positive cash flow per user in approximately three months from install.

The revised Medify model, in simple terms, means that every 1% of UK market penetration equates to $5.1million USD of income, with a Gross Profit margin of $3.9million USD per annum.

CEO Ian O’Reilly, commenting on the work stated, “this activity has been a valuable exercise and revisited the commercial fundamentals of the Medify product suite. It is very encouraging to see an updating of the business model showing sustainable revenue and greater profitability opportunities. This is one of the core basics in support of a planned aggressive marketing campaign in a Q4 timeframe”
Sources:
PR Newswire – Toronto
and
Medify Solutions Ltd.
For further information:
Jonathan Bryant, Group Chairman,
Medify Solutions,
Tel: +44(0)845-034-4090
jbryant@medifysolutions.com

About Medify Solutions, Inc.: The Medify Solutions group of companies are focused on the development, taking to market and delivery of leading edge mobile solutions for the healthcare market. With operations across the EU, Medify are at the forefront of the technology revolution in patient care. Medify Solutions are the first business to have developed a Secure Remote Access product for the Healthcare market – addressing critical requirements of Governmental strategic initiatives, Using the latest integrated mobile client based technologies.

Forward Looking Statements: This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements. The words “estimate,” “project,” “intends,” “expects,” “believes,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbour” provisions of the Private Securities Litigation Reform Act of 1995. For a more complete description of these and other risk factors that may affect the future performance of Medify Solutions Limited, see “Risk Factors” in the Company’s Annual Report on Form 10-KSB and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made and the Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4268. Web: StockGuru.com. Email: Publisher@stockguru.com.

Disclosure: Pentony Enterprises LLC was compensated $15,000 by a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Related Post